Literature DB >> 16937130

Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?

Stephen D Marks, Mary McGraw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16937130     DOI： 10.1007/s00467-006-0260-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  10 in total

1.  Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment.

Authors:  Mark D Pescovitz; Benita K Book; Richard A Sidner
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

2.  B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.

Authors:  Stephen D Marks; Sue Patey; Paul A Brogan; Nathan Hasson; Clarissa Pilkington; Patricia Woo; Kjell Tullus
Journal:  Arthritis Rheum       Date:  2005-10

3.  B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

Authors:  M J Leandro; G Cambridge; J C Edwards; M R Ehrenstein; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2005-09-27       Impact factor: 7.580

4.  Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.

Authors:  J D Hainsworth; H A Burris; L H Morrissey; S Litchy; D C Scullin; J D Bearden; P Richards; F A Greco
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

5.  Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.

Authors:  Kandai Nozu; Kazumoto Iijima; Masato Fujisawa; Atsuko Nakagawa; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

6.  Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Authors:  J C Edwards; G Cambridge
Journal:  Rheumatology (Oxford)       Date:  2001-02       Impact factor: 7.580

Review 7.  Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.

Authors:  Hanadi Kazkaz; David Isenberg
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

8.  Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide.

Authors:  P Cochat; A Kassir; S Colon; C Glastre; B Tourniaire; B Parchoux; X Martin; L David
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

9.  Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.

Authors:  Vasundhara Ganne; Nauman Siddiqi; Bal Kamaplath; Chung-Che Chang; Eric P Cohen; Barbara A Bresnahan; Sundaram Hariharan
Journal:  Clin Transplant       Date:  2003-10       Impact factor: 2.863

Review 10.  B cell depletion in autoimmune disease.

Authors:  Claire Gorman; Maria Leandro; David Isenberg
Journal:  Arthritis Res Ther       Date:  2003-10-02       Impact factor: 5.156
  10 in total
  16 in total

1.  Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.

Authors:  Alessia Fornoni; Junichiro Sageshima; Changli Wei; Sandra Merscher-Gomez; Robier Aguillon-Prada; Alexandra N Jauregui; Jing Li; Adela Mattiazzi; Gaetano Ciancio; Linda Chen; Gaston Zilleruelo; Carolyn Abitbol; Jayanthi Chandar; Wacheree Seeherunvong; Camillo Ricordi; Masami Ikehata; Maria Pia Rastaldi; Jochen Reiser; George W Burke
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis.

Authors:  Juhi Kumar; Ibrahim F Shatat; Amy L Skversky; Robert P Woroniecki; Marcela Del Rio; Eduardo M Perelstein; Valerie L Johnson; Shefali Mahesh
Journal:  Pediatr Nephrol       Date:  2012-10-04       Impact factor: 3.714

Review 3.  Update on the treatment of focal segmental glomerulosclerosis in renal transplantation.

Authors:  Maria Messina; Ester Gallo; Alberto Mella; Fabiola Pagani; Luigi Biancone
Journal:  World J Transplant       Date:  2016-03-24

Review 4.  Indications for use and safety of rituximab in childhood renal diseases.

Authors:  Kjell Tullus; Stephen D Marks
Journal:  Pediatr Nephrol       Date:  2012-09-21       Impact factor: 3.714

Review 5.  Nephrotic syndrome and rituximab: facts and perspectives.

Authors:  Dieter Haffner; Dagmar-Christiane Fischer
Journal:  Pediatr Nephrol       Date:  2009-06-04       Impact factor: 3.714

Review 6.  Recent progress in the pathophysiology and treatment of FSGS recurrence.

Authors:  P Cravedi; J B Kopp; G Remuzzi
Journal:  Am J Transplant       Date:  2013-01-11       Impact factor: 8.086

Review 7.  Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?

Authors:  Jörg Dötsch; Dirk E Müller-Wiefel; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2007-09-26       Impact factor: 3.714

8.  Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis.

Authors:  Gema Fernandez-Fresnedo; Alfonso Segarra; Ester González; Simona Alexandru; Ramon Delgado; Natalia Ramos; Jesús Egido; Manuel Praga
Journal:  Clin J Am Soc Nephrol       Date:  2009-07-02       Impact factor: 8.237

9.  Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis.

Authors:  Gian Marco Ghiggeri; Luca Musante; Giovanni Candiano; Maurizio Bruschi; Laura Santucci; Giancarlo Barbano; Antonella Trivelli; Lucia Rivabella; Rosanna Gusmano; Francesco Perfumo
Journal:  Pediatr Nephrol       Date:  2007-07-28       Impact factor: 3.714

Review 10.  Disease recurrence in paediatric renal transplantation.

Authors:  Pierre Cochat; Sonia Fargue; Guillaume Mestrallet; Therese Jungraithmayr; Paulo Koch-Nogueira; Bruno Ranchin; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2009-02-27       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.